China Biotechnology Market Key Takeaways

• The China biotechnology market was valued at USD 89 billion in 2025 and is projected to grow from USD 93 billion in 2026 to USD 129 billion by 2032, registering a CAGR of 5.6% during 2026–2032.
• By technology, DNA sequencing remains the leading segment, accounting for an estimated 27.8% market share in 2026.
• By component type, instruments & equipment dominate the market with an estimated 36.4% share in 2026.
• The market is highly fragmented, with the top five companies collectively accounting for an estimated 14% market share in 2026.

China Biotechnology Market Size & Outlook

The biotechnology market in China is projected to expand from USD 93 billion in 2026 to USD 129 billion by 2032, registering a CAGR of 5.6% during the forecast period.

Industry Growth is primarily supported by increasing commercialization of innovative biologics, expanding contract development and manufacturing (CDMO) services, and rising adoption of precision medicine. Continuous investments in advanced therapeutics and domestic biomanufacturing are further strengthening the China biotechnology market while creating new opportunities across pharmaceutical research and industrial biotechnology.

China's large healthcare industry continues to provide a strong commercial foundation for biotechnology expansion. According to the National Health Commission (NHC), China's total healthcare expenditure exceeded approximately USD 1.28 trillion in 2024, supported by increasing demand for advanced diagnostics, biologics, and specialty therapeutics. Rising healthcare spending is accelerating investments in biotechnology innovation, clinical research, and high-value biologics, strengthening the biopharmaceutical ecosystem and expanding opportunities for domestic biotechnology companies.

The market outlook is further reinforced by the scale of China's pharmaceutical industry. According to the National Bureau of Statistics (NBS), the pharmaceutical manufacturing industry generated operating revenue exceeding USD 419 billion in 2024. The rapid expansion of biologics manufacturing, antibody therapeutics, vaccines, and cell and gene therapy production is increasing the contribution of biotechnology to pharmaceutical revenues, supporting the growth of the biologics manufacturing market and encouraging continuous capacity expansion by leading domestic companies.

Looking ahead, biotechnology commercialization is expected to accelerate as China continues strengthening clinical translation, advanced manufacturing, and international partnerships. Government support for innovative medicines, expanding CDMO capabilities, and increasing adoption of precision diagnostics are creating favorable conditions for sustained market growth. These structural developments are expected to enhance the country's competitiveness in the China life sciences market while reinforcing long-term opportunities across the advanced biopharmaceutical industry.

China Biotechnology Market Key Indicators

• According to the World Health Organization (WHO), China recorded approximately 4.82 million new cancer cases in 2024, making oncology the largest demand generator for monoclonal antibodies, cell therapies, and other advanced biologics, supporting sustained growth of the China biotechnology industry.
• Despite strong domestic production, China imported approximately USD 1.4 billion worth of diagnostic and laboratory reagents and USD 125 million of prepared cell culture media from the United States in 2024, highlighting continued reliance on advanced biotechnology research inputs and supporting growth in the biologics supply chain.
• As per the National Medical Products Administration (NMPA), China approved 55 rare disease medicines in 2024, reflecting the country's accelerating focus on orphan drug innovation, advanced biologics, and next-generation biotechnology therapies targeting unmet medical needs.

China Biotechnology Market Scope

Category	Segments
By Component Type	Instruments & Equipment, Reagents and Consumables, Software, Services
By Technology	Sequencing, PCR, Cell Culture, Fermentation, Chromatography, CRISPR, Bioinformatics, Others
By Application	Healthcare Biotechnology, Agricultural Biotechnology, Industrial Biotechnology, Environmental Biotechnology, Research

China Biotechnology Market Growth Driver

Rising Innovation Investment and Accelerated Commercialization of Advanced Biologics

China's biotechnology industry is witnessing robust growth due to sustained investments in scientific research and the rapid commercialization of innovative biologics. According to the National Bureau of Statistics, China's research and development (R&D) expenditure reached approximately USD 496.3 billion in 2024, reflecting continued government and private-sector support for high-value innovation. The expansion of research funding is strengthening biotechnology innovation, advancing biologics development, and fostering breakthroughs in precision medicine, antibody therapeutics, and advanced biomanufacturing, reinforcing the long-term outlook for the China biotechnology market.

The commercialization ecosystem is further supported by a more efficient regulatory framework for innovative medicines. The National Medical Products Administration (NMPA) approved 48 first-in-class innovative drugs in 2024 across multiple therapeutic areas through accelerated review pathways, encouraging greater investment in novel biologics and advanced therapies. Faster regulatory approvals, expanding clinical development capabilities, and increasing industry collaboration are enhancing the country's biopharmaceutical market competitiveness, enabling domestic companies to strengthen their global presence while driving sustainable market expansion over the forecast period.

Recent Trends

Innovative Drugs Are Gaining Stronger Policy Support

China is accelerating the commercialization of innovative medicines through continuous regulatory and policy reforms. In 2025, the National Medical Products Administration (NMPA) approved a series of Category 1 innovative drugs under its priority review pathway, including Akeso's Ivonescimab Injection, a first-in-class PD-1/VEGF bispecific antibody for EGFR-mutated non-small cell lung cancer, and Dizal's Golidocitinib Capsules for relapsed or refractory peripheral T-cell lymphoma. These approvals demonstrate the government's commitment to expediting breakthrough therapies and strengthening the innovative biologics market.

Policy support is further reinforced through comprehensive pharmaceutical regulatory reforms. The General Office of the State Council's 2024 Opinions on deepening drug and medical device regulation have prompted the NMPA to introduce measures that accelerate the availability of innovative and clinically urgent medicines, including allowing pre-approval commercial-scale batches of eligible overseas-marketed innovative drugs to enter the Chinese market more rapidly. These initiatives are improving commercialization efficiency, encouraging global licensing activities, and enhancing China's competitiveness in the China biopharmaceutical industry and next-generation therapeutics ecosystem.

China Biotechnology Market Opportunities and Challenges

Nanoscale Manufacturing Bottlenecks Create Opportunities for Specialized Nano-CDMOs

The commercialization of nanobiotechnology in China is increasingly constrained by the challenge of scaling nanoparticle manufacturing from laboratory research to industrial production. Maintaining uniform nanoparticle sizes below 100 nanometers, preserving the stability of lipid nanoparticles (LNPs), and minimizing batch variability remain major technical barriers during large-scale manufacturing. These challenges are particularly critical for mRNA therapeutics, gene therapies, and targeted nanomedicines, where even slight deviations can affect product efficacy and safety. As China accelerates the development of advanced biologics, overcoming these manufacturing bottlenecks is becoming essential for the nanomedicine manufacturing ecosystem and broader biotechnology scale-up capabilities.

This scalability gap is creating substantial opportunities for specialized Nano-CDMOs and advanced bioprocess technology providers. In 2024, WuXi XDC Cayman Inc. expanded its integrated antibody-drug conjugate (ADC) discovery and manufacturing platform to support increasing global demand for complex biologics requiring precision conjugation and nanoscale process control. Simultaneously, companies are investing in industrial microfluidic systems, AI-enabled process monitoring, and proprietary lipid nanoparticle (LNP) delivery platforms to improve manufacturing consistency and reduce batch failures. These technology advancements are strengthening China's nano-CDMO market, enabling faster commercialization of next-generation therapeutics while supporting the country's ambition to become a global hub for advanced biomanufacturing.

Segmentation Insights

DNA Sequencing Emerges as the Foundation of China's Biotechnology Innovation Ecosystem

DNA Sequencing Dominates the industry with a 27.8% market share of the China biotechnology market in 2026, supported by its expanding role in precision medicine, oncology, and genomic research. According to the National Medical Products Administration (NMPA), 128 gene therapy clinical trials were approved in 2024, significantly increasing the demand for sequencing technologies used in biomarker identification and patient stratification. This growing adoption continues to strengthen China's genomic sequencing market and accelerate innovation in advanced molecular diagnostics.

The segment is further supported by continuous investments in domestic sequencing platforms and clinical genomics infrastructure. In 2024, MGI Tech Co., Ltd. launched the DNBSEQ-T1+ high-throughput sequencing platform, capable of generating up to 6 terabases (Tb) of sequencing data per run, improving efficiency for clinical and pharmaceutical research. The commercialization of advanced sequencing systems is reinforcing the precision genomics industry while supporting the rapid expansion of the life science sequencing technologies ecosystem. Based on technology type, the industry is segmented into:

• DNA Sequencing
• Nanobiotechnology
• PCR Technology
• Fermentation
• Chromatography
• CRISPR & Gene-Editing Tools
• Cell Based Assays
• Others

Instrument & Equipment Segment Shape China's Next Generation of Biotechnology Growth and Adoption

Instruments & equipment segment dominates the industry, accounts for 36.4% of the China biotechnology industry in 2026, supported by sustained investments in high-tech manufacturing and laboratory infrastructure. According to the National Bureau of Statistics (NBS), investment in equipment and apparatus purchases increased by 15.7% in 2024, the fastest-growing category within fixed-asset investment. Additionally, high-tech manufacturing value-added rose 8.9%, while investment in scientific research and technology services increased 11.8%, reflecting rising procurement of sequencing platforms, bioprocessing systems, chromatography equipment, and laboratory automation solutions across biotechnology facilities. These trends continue to strengthen the biotechnology instruments market.

The segment is further supported by China's strategic focus on domestic technology development and laboratory modernization. According to the NBS, R&D expenditure reached USD 507 billion in 2024, increasing 8.3% year-on-year. In parallel, domestic manufacturers are expanding their presence in advanced biotechnology equipment, while government-backed investments continue to accelerate local production of sequencing and laboratory platforms. These developments are improving equipment self-sufficiency and creating new growth opportunities across the laboratory equipment market and bioprocessing technology industry. By the product type the industry is segmented into:

• Instruments & Equipment
• Reagents and Consumables
• Software
• Services

China Biotechnology Market Competitive Analysis

The China biotechnology industry remains highly fragmented, with the top five companies accounting for approximately 14% of the total market in 2026. Companies continue to compete through biologics innovation, CDMO expansion, global licensing, and cell & gene therapy development, strengthening the China biotech competitive landscape and biopharmaceutical innovation ecosystem.

Top Leading Companies of China Biotechnology Industry:

• BeiGene, Ltd.
• WuXi AppTec Co., Ltd.
• WuXi Biologics (Cayman) Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Innovent Biologics, Inc.
• CSPC Pharmaceutical Group Limited
• Sino Biopharmaceutical Limited
• Legend Biotech Corporation
• 3SBio Inc.
• Akeso, Inc.

China Biotechnology Industry News and Recent Developments

January 2025: WuXi Biologics Agrees to Sell Ireland Vaccine Manufacturing Facility to Merck & Co.

WuXi Biologics (Cayman) Inc. announced the sale of its vaccine manufacturing facility in Dundalk, Ireland, to Merck & Co., Inc. for approximately USD 500 million. The transaction enables WuXi Biologics to optimize its global manufacturing network while allowing Merck to strengthen its vaccine production capabilities in Europe.

Impact Analysis: The divestment allows WuXi Biologics to reallocate capital toward higher-growth biologics and CRDMO operations while improving operational efficiency. The transaction also reflects the strategic restructuring of Chinese biotechnology companies amid evolving global supply chain dynamics, supporting continued investment in high-value biologics manufacturing and biopharmaceutical outsourcing.

November 2024: Merck & Co. Signs Up to USD 3.3 Billion Licensing Agreement with LaNova Medicines

Merck & Co., Inc. entered into an exclusive global licensing agreement with LaNova Medicines Co., Ltd. for LM-299, an investigational PD-1/VEGF bispecific antibody. The agreement is valued at up to USD 3.3 billion, including an upfront payment of USD 588 million and potential milestone payments.

Impact Analysis: The agreement highlights the growing international value of innovative biologics developed by Chinese biotechnology companies. Large-scale licensing partnerships are expected to accelerate global commercialization of China-origin drug candidates, increase foreign investment, and reinforce China's position as an emerging source of first-in-class oncology therapies and cross-border biotechnology innovation.